Response to "Letter to the Editor: Vaccine Failures in Pediatric Cases Caused by Streptococcus pneumoniae Serotype 19A"

• Published in: Human vaccines & immunotherapeutics Vol. 16; no. 10; pp. 2511 - 2512
• Main Authors: Gönüllü, Erdem, Soysal, Ahmet, Yıldız, İsmail, Aydemir, Gökhan, Tunç, Turan, Karaböcüoğlu, Metin
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 02-10-2020; Taylor & Francis Group
• Subjects: Child; community-acquired pneumonia; Hospitalization; Humans; Immunization Programs; Incidence; invasive pneumococcal disease; Letter; Letter To The Editor; Pediatric; Pneumococcal Vaccines; Pneumonia; Serogroup; Streptococcus pneumoniae - immunology; Turkey - epidemiology; Vaccines, Conjugate; Turkey; community-acquired pneumonia; Pediatric; invasive pneumococcal disease
• ISSN: 2164-5515; 2164-554X
• DOI: 10.1080/21645515.2020.1769397

We are happy to answer to the Letter from Ozkaya-Parlakay et al. to the Editor commenting on our recent paper, 1  investigated impact of the 13-valent pneumococcal conjugate vaccine (PCV13)  on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program (NIP) of Turkey.   Ozkaya-Parlakay et al. draw attention to vaccine failure and importance of continuous  surveillance of relevant disease especially in the perspective of  Streptococcus pneumoniae  serotype 19A. They supported their opinion by their clinical observation of seven children who were vaccinated with PCV13 developed empyema and meningitidis caused by Streptococcus pneumoniae  serotype 19A 
 in Turkey.